Statistical Models for Screening: Planning Public Health Programs

  • Sandra J. Lee
  • Marvin Zelen
Part of the Cancer Treatment and Research book series (CTAR, volume 113)


The previous chapter discusses the general ideas associated with modeling the early detection of disease. In particular, the chapter discusses the role of models in considering the quantitative aspects of the early detection of disease. In this chapter, it will be assumed that clinical trials have established the benefit of early detection of disease and we will discuss the issues in bringing these benefits to widespread public health use.


Breast Cancer Breast Cancer Screening Sojourn Time Screen Program Threshold Method 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Albert, A., Gertman, P. M., Lois, T. and Liu, S. (1978). Screening for the early detection of cancer II. The impact of screening in the natural history of the disease. Mathematical Bioscience 40, 61–109.CrossRefGoogle Scholar
  2. Baker, S. G. (1998). Evaluating the age to begin periodic breast cancer screening using data from a few regularly scheduled screenings. Biometrics 54, 156–978.CrossRefGoogle Scholar
  3. Baker, S. G. and Chu, K.C. (1990). Evaluating screening for the early detection and treatment of cancer without using a randomized control group. Journal of the American Statistical Association 85, 321–27.CrossRefGoogle Scholar
  4. Berry, D. A. (1998). Benefits and risks of screening mammography for women in their forties: a statistical approach. Journal of the National Cancer Institute 90:19, 1431–9.Google Scholar
  5. Chen, H. H., Duffy, D. W. and Tabar, L. (1996). A markov chain method to estimate the tumor progression rate from preclinical to clinical phase, sensitivityGoogle Scholar
  6. and positive predictive value for mammography in breast cancer screening. Statistician 45 307–17.Google Scholar
  7. Chen, H. H., Duffy, D. W., Tabar, L. and Day, N.E. (1997). Markov chain models for progression of breast cancer-Part I: tumor attributes and the preclinical screen-detectable phase. Journal of Epidemiology and Biostatistics 2:1 923.Google Scholar
  8. Day, N. E. and Walter, S. D. (1984). Simplified models of screening of chronic disease: estimation procedures from mass screening programs. Biometrics 40, 1–13.PubMedCrossRefGoogle Scholar
  9. Day, N. E., Walter, S. D. and Tabar, L. (1988). The sensitivity and lead time of breast cancer screening: A comparison of the results of different studies. In Screening for Breast Cancer, Ed. N. E. Day and A. B. Miller, pp. 105–9. Stuttgart: Hans Huber.Google Scholar
  10. Duffy, S.W., Chen, H. H., Tabar, L. and Day, N. E. (1995). Estimation of mean sojourn time in breast cancer screening using a markov chain model of both entry to and exit from the preclinical detectable phase. Statistics in Medicine 14, 1531–43.PubMedCrossRefGoogle Scholar
  11. Dubin, N. (1981). Predicting the benefit of screening for disease. Journal of Applied Probability 18 348–60.CrossRefGoogle Scholar
  12. Eddy, D. M. (1980). Screening for Cancer: Theory, Analysis and Design. Englewood Cliffs, NJ: Prentice-Hall.Google Scholar
  13. Eddy, D. M. (1983). A mathematical model for timing repeated medical tests. Medical Decision Making 3, 34–62.Google Scholar
  14. Eddy, D. M and Shwartz, M. (1982). Mathematical models in screening. In: Schottenfeld D, Fraumeni J eds. Cancer epidemiology and prevention. Philadelphia: W.B. Saunders, pp. 1075–90.Google Scholar
  15. Etzioni, R. D., Connor, R. J., Prorok, P. C. and Self, S. G. (1995). Design and analysis of cancer screening trials. Statistical Methods in Medical Research 4, 3–17.PubMedCrossRefGoogle Scholar
  16. Gail, M. H., Brinton, L. A., Byar, D. P., Corle, D. K., Green, S. B., Schairer, C. and Mulvihill, J. J. (1989). Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. Journal of the National Cancer Institute 81, 1879–86.PubMedCrossRefGoogle Scholar
  17. Gail, M. H. and Rimer, B. (1998). Risk-based recommendations for mammographic screening for women in their forties. Journal of Clinical Oncology 16, 3105–14.PubMedGoogle Scholar
  18. Habbema, J. D. F., VanOortmarssen, G. J., Lubbe J. T. N. and van derMass P. J. (1984). The MISCAN simulation program for the evaluation of screening for disease. Computer Programs in Biomedicine 9.Google Scholar
  19. Hu, P. and Zelen, M. (1997). Planning clinical trials to evaluate early detection programs. Biometrika 84, 817–29.CrossRefGoogle Scholar
  20. Kirch, R. L. A. and Klein, M. (1974). Examination schedules for breast cancer. Cancer 33, 1444–50.PubMedCrossRefGoogle Scholar
  21. Kirch, R. L. A. and Klein, M. (1979). Surveillance Schedules for medical examinations. Management Science 20, 1403–9.CrossRefGoogle Scholar
  22. Knox, E. G. (1973). A simulation system for screening procedures. In: McLachlan G ed. The future and present indicatives, problems and progress in medical care, Ninth Series, Nuffield Provincial Hospitals Trust. London: Oxford University Press, pp. 17–55.Google Scholar
  23. Lee, S. J. and Zelen, M. (1998). Scheduling periodic examinations for the early detection of disease: applications to breast cancer. Journal of the American Statistical Association 93, 1271–81.CrossRefGoogle Scholar
  24. Lincoln, T. L. and Weiss, G. H. (1964) A statistical evaluation of recurrent medical examinations. Operations Research 12, 187–205.CrossRefGoogle Scholar
  25. Miller, A. B., Baines, C. J., To, T. and Wall, C. (1992a) Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 40 to 49 years. Canadian Medial Association Journal 147:10, 1459–76.Google Scholar
  26. Miller, A. B., Baines, C. J., To, T. and Wall, C. (1992b) Canadian National Breast Screening Study: 1. Breast cancer detection and death rates among women aged 50 to 59 years. Canadian Medial Association Journal 147:10, 1477–88.Google Scholar
  27. NIH Consensus Statement. Breast cancer screening for women ages 40–49, January 21–23, 1997. Bethesda, MD. NCI, 1997.Google Scholar
  28. Parmigiani, G. (1993). On optimal screening ages. Journal of the American Statistical Association 88, 622–28.CrossRefGoogle Scholar
  29. Parmigiani, G. (1997). Timing medical examinations via intensity functions. Biometrika 84, 803–16.CrossRefGoogle Scholar
  30. Prorok, P. C. (1976a). The theory of periodic screening I. Lead time and proportion detected. Advanced Applied Probability 8, 127–43.CrossRefGoogle Scholar
  31. Prorok, P. C. (1976b). The theory of periodic screening II. Doubly bounded recurrence times and mean lead time and detection probability estimation. Advanced Applied Probability 8, 460–76.CrossRefGoogle Scholar
  32. Shapiro, S. (1977). Evidence of screening for breast cancer form a randomized trial. Cancer 39, 2772–82.PubMedCrossRefGoogle Scholar
  33. Shapiro, S., Venet, W., Strax, P. H., Venet, L. and Rosener, R. (1982). Ten to fourteen year effect of screening on breast cancer mortality. Journal of the National Cancer Institute 69, 349–55.PubMedGoogle Scholar
  34. Shapiro, S., Venet, W., Strax, P. and Venet. L. (1988). Periodic Screening for Breast Cancer. The Health Insurance Plan Project and its Sequelae, 19631986. Baltimore, MD: The Johns Hopkins University Press.Google Scholar
  35. Shen, Y. and Zelen, M. (1999). Parametric estimation procedures for screening programmes: stable and nonstable disease models for multimodality case finding. Biometrika 86, 503–15.CrossRefGoogle Scholar
  36. Shwartz, M. (1978). An analysis of the benefits of serial screening for breast cancer based upon a mathematical model of the disease. Cancer 41, 1550–64.PubMedCrossRefGoogle Scholar
  37. Shwartz, M. and Plough, A. L. (1984). Models in planning cancer programs. In Cornell RG ed. Statistical methods for cancer studies. Marcel Dekker, New York, pp. 329–416.Google Scholar
  38. Stomper, P.C. and Gelman, B. S. (1989). Mammography in symptomatic and asymptomatic patients. Hematologic Oncology ofNorthAmerica 3:4 611–40.Google Scholar
  39. Straatman, H., Peer, P. G. M. and Verbeek, A. L. (1997). Estimating lead time and sensitivity in a screening program without estimating incidence in the screened group. Biometrics 53, 217–29.PubMedCrossRefGoogle Scholar
  40. Struewing, J.P., Hartge, P., Wacholder, S., Baker, S. M., Berlim, M., McAdams, M., Timmerman, M. M., Brody, L.C. and Tucker, M.A (1997). The Risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. New England Journal of Medicine 11, 1401–8.CrossRefGoogle Scholar
  41. Walter, S. D. and Day, N. E. (1983). Estimation of the duration of a pre-clinical disease state using screening data. American Journal of Epidemiology 118, 856–86.Google Scholar
  42. Zelen, M. (1993). Optimal scheduling of examinations for the early detection of disease. Biometrika 80, 279–93.CrossRefGoogle Scholar
  43. Zelen, M. and Feinleib, M. (1969). On the theory of screening for chronic diseases. Biometrika 56, 601–14.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2002

Authors and Affiliations

  • Sandra J. Lee
    • 1
  • Marvin Zelen
    • 1
  1. 1.Department of BiostatisticsHarvard School of Public Health and Dana-Farber Cancer InstituteUSA

Personalised recommendations